¼¼°èÀÇ »ïÂ÷ ½Å°æÅë Ä¡·á ½ÃÀå º¸°í¼­(2025³â)
Trigeminal Neuralgia Treatment Global Market Report 2025
»óǰÄÚµå : 1720914
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,253,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,039,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,824,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

»ïÂ÷ ½Å°æÅë Ä¡·á ½ÃÀå ±Ô¸ð´Â ¾ÕÀ¸·Î ¼ö³â°£ °­·ÂÇÑ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. 2029³â¿¡´Â CAGR 6.7%·Î 9¾ï 5,000¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø±â°£ÀÇ ¼ºÀåÀº ÇコÄɾî Àü¹®°¡³ª ÀϹÝÁÖ¹ÎÀÇ »ïÂ÷ ½Å°æÅë¿¡ ´ëÇÑ ÀÎÁöµµÀÇ Çâ»ó, TN»ç·Ê Áõ°¡, ³ëÀÎ Áõ°¡, ÀÇ·áºñ Áõ°¡, Áø´Ü»ç·Ê ¼ö Áõ°¡ µî¿¡ ±âÀÎÇÏ´Â °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ½Å°æÁ¶Àý ±â¼úÀÇ Áøº¸, Á¶»ç ±â¼úÀÇ Çâ»ó, ÀÇ·á ¿¬±¸¿Í ±â¼úÀÇ Áøº¸, Àúħ½À ¼ö¼ú ±â¼úÀÇ Ã¤ÅÃ, µðÁöÅÐ Çコ ±â¼úÀÇ ÅëÇÕ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù.

½Å°æÁúȯÀÇ À¯º´·ü Áõ°¡´Â ¾ÕÀ¸·Î ¼ö ³â°£ »ïÂ÷ ½Å°æÅë Ä¡·á ½ÃÀåÀÇ È®´ë¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ½Å°æ Áúȯ¿¡´Â ³ú, ô¼ö, ½Å°æÀ» Æ÷ÇÔÇÑ ½Å°æ°è¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁúȯÀÌ Æ÷ÇԵ˴ϴÙ. À¯ÀüÀû ¼ÒÀÎ, °¨¿°, ¿Ü»ó, µ¶¼Ò, ÀÚ°¡¸é¿ª ¹ÝÀÀ, º¯¼º µî ´Ù¾çÇÑ ¿äÀεéÀÌ ÀÌ·¯ÇÑ Áúº´ÀÇ À¯º´·ü »ó½Â¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. »ïÂ÷ ½Å°æÅë Ä¡·á´Â ½ÉÇÑ ¾È¸é ÅëÁõ ¿ÏÈ­, ½Å°æ ÀÚ±Ø ¿ÏÈ­, QOL Çâ»ó, ÅëÁõ °ü¸®, Ãß°¡ ½Å°æ Àå¾Ö ¿¹¹æÀ» ÅëÇØ ½Å°æ Áúȯ ȯÀÚ¸¦ Áö¿øÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 4¿ù º§±â¿¡¿¡ ±â¹ÝÀ» µÐ ºñ¿µ¸® ´ÜüÀÎ European Brain CouncilÀÇ µ¥ÀÌÅÍ¿¡ µû¸£¸é, 600°³ ÀÌ»óÀÇ ½Å°æÁúȯ°ú 300°³ÀÇ Á¤½ÅÁúȯÀÌ Àü ¼¼°è ¼ö¹é¸¸ ¸í¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç 6,500¸¸ ¸íÀÇ °£ÁúȯÀÚ°¡ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. À¯·´¸¸À¸·Îµµ 1,050¸¸¸íÀÌ Ä¡¸ÅÀ̸ç, 2050³â¿¡´Â 1,870¸¸¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ±× °á°ú, ½Å°æÁúȯÀÇ ÀÌȯÀ² Áõ°¡°¡ »ïÂ÷ ½Å°æÅë Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

»ïÂ÷ ½Å°æÅë Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä±â¾÷Àº ±ÔÁ¦´ç±¹ÀÇ ½ÂÀÎÀ» ¹Þ¾Æ ½ÃÀå¿¡¼­ÀÇ Á¸À縦 È®´ëÇϱâ À§ÇØ ½ÃÇè¿ë ½Å¾à(IND) ½Åû¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. IND ½ÅûÀ» ÅëÇØ Á¦¾à ȸ»ç´Â ±ÔÁ¦ ´ç±¹¿¡ ½ÂÀÎÀ» ¿äûÇÏ¿© ÀÎü ÀÓ»ó °Ë»ç¸¦ ½ÃÀÛÇϰí ÀǾàǰÀÇ ¾ÈÀü¼º, È¿´É ¹× ÀûÀýÇÑ º¹¿ë·®À» Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ½ºÀ§½º¿¡ ±â¹ÝÀ» µÐ ÀÓ»ó ´Ü°èÀÇ »ý¸í °øÇÐ ±â¾÷ÀÎ Noema Pharma´Â 2022³â 2¿ù, »ïÂ÷ ½Å°æÅë(TN)À» ´ë»óÀ¸·Î mGluR5 ¾ïÁ¦Á¦ NOE-101ÀÇ 2b»ó ÀÓ»ó °Ë»ç¸¦ ½ÃÀÛÇϱâ À§ÇÑ IND ½ÂÀÎÀ» ¹Ì±¹ ½ÄǰÀǾ౹(FDA)À¸·ÎºÎÅÍ ÃëµæÇß½À´Ï´Ù. LibraTN ¿¬±¸´Â ¼ºÀÎÀÇ »ïÂ÷ ½Å°æÅë(TN) °ü·Ã ÅëÁõ¿¡ ´ëÇÑ NOE-101ÀÇ È¿´É°ú ¾ÈÀü¼ºÀ» Æò°¡ÇÏ´Â 24ÁÖ°£ÀÇ ´Ù±â°ü, À§¾à ´ëÁ¶ ÀÓ»ó½ÃÇèÀ̸ç, 2024³â »ó¹Ý±â¿¡ °á°ú°¡ ³ª¿Ã ¿¹Á¤ÀÔ´Ï´Ù. ¶ÇÇÑ FDA´Â ¹Ù½É ±Û·ç¶õÆ®(NOE-101)ÀÇ °³¹ß°ú ¾à»ç ½É»ç ÇÁ·Î¼¼½º¸¦ °¡¼ÓÈ­Çϱâ À§ÇØ ÆÐ½ºÆ® Æ®·¢ ÁöÁ¤À» ½Ç½ÃÇß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - °Å½Ã°æÁ¦ ½Ã³ª¸®¿À ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°ÀÇ ¿µÇâ°ú ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, Àü·«

Á¦36Àå ºÎ·Ï

SHW
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Trigeminal neuralgia treatment involves medical strategies to manage the severe, sharp facial pain caused by trigeminal neuralgia, which affects the trigeminal nerve. The primary goal of treatment is to alleviate pain, reduce the frequency and intensity of episodes, and address underlying nerve irritation, ultimately improving the patient's quality of life.

The main types of trigeminal neuralgia treatment include medications, surgery, and other therapeutic approaches. Medications are formulated to reduce pain by controlling nerve activity. These treatments are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and are utilized by several end-users, such as hospitals, specialty clinics, and ambulatory surgical centers.

The trigeminal neuralgia treatment market research report is one of a series of new reports from The Business Research Company that provides trigeminal neuralgia treatment market statistics, including the trigeminal neuralgia treatment industry global market size, regional shares, competitors with the trigeminal neuralgia treatment market share, detailed trigeminal neuralgia treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the trigeminal neuralgia treatment industry. This trigeminal neuralgia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The trigeminal neuralgia treatment market size has grown strongly in recent years. It will grow from $0.68 billion in 2024 to $0.73 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth during the historic period can be attributed to the increasing incidence of chronic diseases, the rising prevalence of neurological disorders and trigeminal neuralgia, the growing demand for minimally invasive treatments, and the increasing preference for minimally invasive surgeries.

The trigeminal neuralgia treatment market size is expected to see strong growth in the next few years. It will grow to $0.95 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to increasing awareness of trigeminal neuralgia among healthcare professionals and the general population, a rise in TN cases, a growing geriatric population, increasing healthcare expenditure, and a higher number of diagnosed cases. Major trends include advancements in neuromodulation techniques, improvements in TENS technology, progress in medical research and technology, the adoption of minimally invasive surgical techniques, and the integration of digital health technologies.

The increasing prevalence of neurological disorders is expected to drive the expansion of the trigeminal neuralgia treatment market in the coming years. Neurological disorders encompass conditions that affect the nervous system, including the brain, spinal cord, and nerves. Various factors contribute to the rising prevalence of these disorders, such as genetic predisposition, infections, trauma, toxins, autoimmune responses, and degeneration. Trigeminal neuralgia treatment helps neurological patients by alleviating severe facial pain, reducing nerve irritation, improving quality of life, managing pain, and preventing further neurological damage. For example, in April 2022, data from the European Brain Council, a Belgium-based non-profit organization, indicated that more than 600 neurological diseases and nearly 300 psychiatric conditions impact millions worldwide, including 65 million people with epilepsy. In Europe alone, 10.5 million individuals have dementia, with projections estimating an increase to 18.7 million by 2050. Consequently, the growing incidence of neurological disorders is expected to fuel the demand for trigeminal neuralgia treatments.

Leading companies in the trigeminal neuralgia treatment market are focusing on investigational new drug (IND) applications to obtain regulatory approvals and expand their market presence. An IND application allows pharmaceutical companies to seek approval from regulatory agencies to begin human clinical trials, assessing a drug's safety, efficacy, and appropriate dosage. For instance, in February 2022, Noema Pharma, a Switzerland-based clinical-stage biotechnology company, received IND approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2b clinical trial for the mGluR5 inhibitor NOE-101 in trigeminal neuralgia (TN). The LibraTN study is a 24-week, multi-center, placebo-controlled trial evaluating the efficacy and safety of NOE-101 in adults experiencing TN-related pain, with results expected in the first half of 2024. Additionally, the FDA granted fast track designation to basimglurant (NOE-101) to accelerate its development and regulatory review process.

In October 2022, Pfizer Inc., a U.S.-based pharmaceutical company, acquired Biohaven Pharmaceuticals for approximately $11.6 billion. This acquisition aims to strengthen Pfizer's neurology portfolio by securing full rights to Biohaven Pharmaceuticals' migraine treatments, including Nurtec ODT (rimegepant) and other CGRP receptor antagonists. The deal enhances Pfizer's leadership in the migraine treatment market while expanding its pipeline of innovative neurological therapies. Biohaven Pharmaceuticals, a U.S.-based pharmaceutical company, has also been involved in researching and developing potential treatments for trigeminal neuralgia, including rimegepant.

Major players in the trigeminal neuralgia treatment market are Aetna Inc., Thermo Fisher Scientific Inc., Novartis AG, Sandoz, Sun Pharmaceutical Industries Ltd., Apotex Inc., Lupin Limited, Taro Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Kriya Therapeutics, Convergence Pharmaceuticals Limited, Noema Pharma AG, Max Healthcare, Initiator Pharma AS, Coda Biotherapeutics Inc., Oxford Cannabinoid Technologies Holdings Plc, NanoVibronix, Biogen Idec, Shanghai SIMR Biotechnology Co. Ltd., Capnia Inc.

North America was the largest region in the trigeminal neuralgia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the trigeminal neuralgia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The trigeminal neuralgia treatment market consists of revenues earned by entities by providing services such as physical therapy, patient education, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The trigeminal neuralgia treatment market also includes sales of anticonvulsants, muscle relaxants, and tricyclic antidepressants (TCAs). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Trigeminal Neuralgia Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on trigeminal neuralgia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for trigeminal neuralgia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The trigeminal neuralgia treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Trigeminal Neuralgia Treatment Market Characteristics

3. Trigeminal Neuralgia Treatment Market Trends And Strategies

4. Trigeminal Neuralgia Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Trigeminal Neuralgia Treatment Growth Analysis And Strategic Analysis Framework

6. Trigeminal Neuralgia Treatment Market Segmentation

7. Trigeminal Neuralgia Treatment Market Regional And Country Analysis

8. Asia-Pacific Trigeminal Neuralgia Treatment Market

9. China Trigeminal Neuralgia Treatment Market

10. India Trigeminal Neuralgia Treatment Market

11. Japan Trigeminal Neuralgia Treatment Market

12. Australia Trigeminal Neuralgia Treatment Market

13. Indonesia Trigeminal Neuralgia Treatment Market

14. South Korea Trigeminal Neuralgia Treatment Market

15. Western Europe Trigeminal Neuralgia Treatment Market

16. UK Trigeminal Neuralgia Treatment Market

17. Germany Trigeminal Neuralgia Treatment Market

18. France Trigeminal Neuralgia Treatment Market

19. Italy Trigeminal Neuralgia Treatment Market

20. Spain Trigeminal Neuralgia Treatment Market

21. Eastern Europe Trigeminal Neuralgia Treatment Market

22. Russia Trigeminal Neuralgia Treatment Market

23. North America Trigeminal Neuralgia Treatment Market

24. USA Trigeminal Neuralgia Treatment Market

25. Canada Trigeminal Neuralgia Treatment Market

26. South America Trigeminal Neuralgia Treatment Market

27. Brazil Trigeminal Neuralgia Treatment Market

28. Middle East Trigeminal Neuralgia Treatment Market

29. Africa Trigeminal Neuralgia Treatment Market

30. Trigeminal Neuralgia Treatment Market Competitive Landscape And Company Profiles

31. Trigeminal Neuralgia Treatment Market Other Major And Innovative Companies

32. Global Trigeminal Neuralgia Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Trigeminal Neuralgia Treatment Market

34. Recent Developments In The Trigeminal Neuralgia Treatment Market

35. Trigeminal Neuralgia Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â